Totality outcome of afatinib sequential treatment in patients with
Non-small cell lung cancer (NSCLC)
afatinib
epidermal growth factor receptor (EGFR)
sequential treatment
tyrosine kinase inhibitor (TKI)
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
27
01
2022
accepted:
26
05
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
ppublish
Résumé
Irrespective of the first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor chosen, acquired resistance to therapy is inevitable. Therefore, a key consideration when assessing therapeutic choices is the availability of subsequent treatment options following disease progression. We assessed clinical outcomes in patients who received first-line afatinib treatment with various second-line treatments including osimertinib for patients acquiring the T790M mutation. A total of 737 Median total TOT in cohorts A, B, C, and D were 35.10 months [95% confidence interval (CI): 30.09-43.53 months], 18.80 months (95% CI: 16.92-20.20 months), 12.00 months (95% CI: 10.22-14.98 months), and 42.60 months (95% CI: 30.95-59.23 months), respectively. The ORR of patients given afatinib was 75.7%. In patients with initial brain metastasis without local treatment, the CNS response rate was 67.0% and CNS progression-free survival was 24.70 months (95% CI: 19.84-33.15 months). This study showed that sequential approach of afatinib followed by second line treatment is an effective therapeutic strategy for
Sections du résumé
Background
UNASSIGNED
Irrespective of the first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor chosen, acquired resistance to therapy is inevitable. Therefore, a key consideration when assessing therapeutic choices is the availability of subsequent treatment options following disease progression. We assessed clinical outcomes in patients who received first-line afatinib treatment with various second-line treatments including osimertinib for patients acquiring the T790M mutation.
Methods
UNASSIGNED
A total of 737
Results
UNASSIGNED
Median total TOT in cohorts A, B, C, and D were 35.10 months [95% confidence interval (CI): 30.09-43.53 months], 18.80 months (95% CI: 16.92-20.20 months), 12.00 months (95% CI: 10.22-14.98 months), and 42.60 months (95% CI: 30.95-59.23 months), respectively. The ORR of patients given afatinib was 75.7%. In patients with initial brain metastasis without local treatment, the CNS response rate was 67.0% and CNS progression-free survival was 24.70 months (95% CI: 19.84-33.15 months).
Conclusions
UNASSIGNED
This study showed that sequential approach of afatinib followed by second line treatment is an effective therapeutic strategy for
Identifiants
pubmed: 35958320
doi: 10.21037/tlcr-22-79
pii: tlcr-11-07-1369
pmc: PMC9359965
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1369-1379Informations de copyright
2022 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-79/coif). JHK has acted as an advisor for Merck Sharp & Dohme Corp. (MSD), Ono Pharmaceutical/Bristol Myers Squibb (BMS), AstraZeneca, Yuhan, Genexin, and NeoimmuneTech; has received research funds from AstraZeneca, Böehringer Ingelheim, Daichi Sankyo, and Yuhan; has acted as a speaker for Roche, Böehringer Ingelheim, and Takeda. The other authors have no conflicts of interest to declare.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
Transl Lung Cancer Res. 2020 Oct;9(5):1749-1758
pubmed: 33209598
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
Lung Cancer. 2021 Dec;162:9-15
pubmed: 34649106
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261
Clin Cancer Res. 2011 Mar 1;17(5):1169-80
pubmed: 21248300
Mol Cancer Ther. 2008 Jul;7(7):1880-9
pubmed: 18606718
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Clin Oncol. 2018 Mar 20;36(9):841-849
pubmed: 28841389
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
Int J Clin Oncol. 2015 Aug;20(4):674-9
pubmed: 25336382
Lung Cancer. 2019 Jun;132:126-131
pubmed: 31097085
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
J Pharmacol Exp Ther. 2012 Nov;343(2):342-50
pubmed: 22888144
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Clin Cancer Res. 2018 Jul 1;24(13):3097-3107
pubmed: 29506987
Future Oncol. 2018 Nov;14(27):2861-2874
pubmed: 30336693